Intermediate-dose IPA rescues aged gut barrier via PXR‑AhR‑driven mitochondrial hormesis
Hypothesis
In aged colonic epithelium, chronic low‑grade inflammaging elevates mitochondrial ROS, which drives senescent‑associated secretory phenotype (SASP) and tight‑junction disassembly. We propose that intermediate‑dose indole‑3‑propionic acid (IPA, 10–25 µM) simultaneously activates PXR and AhR to trigger a hormetic mitochondrial response that reverses barrier leakiness without compromising respiration. Specifically, IPA‑bound PXR recruits NRF2 to the promoters of antioxidant genes (SOD2, GPX1) while AhR‑dependent transcription upregulates mitophagy regulators (BNIP3, PINK1). The combined signaling restores mitochondrial membrane potential, lowers cytosolic ROS, and thereby reduces NF‑κB–mediated SASP secretion. Consequently, senescent enterocytes exhibit decreased p16^INK4a^ expression and recover ZO‑1/occludin localization, restoring transepithelial resistance (TEER) to youthful levels.
Testable predictions
- In 24‑month‑old mice, oral gavage with IPA at 15 mg/kg/day (yielding luminal ~15 µM) for 4 weeks will increase colonic crypt PXR and AhR nuclear occupancy (ChIP‑qPCR) and elevate NRF2‑target expression versus vehicle.
- Isolated colonocytes from treated aged mice will show a 30 % rise in basal oxygen consumption rate (OCR) and a 40 % reduction in mitochondrial superoxide (MitoSOX) compared with untreated aged controls, without the OCR suppression seen at >50 µM IPA.
- Senescence burden (p16^INK4a^+ cells per crypt) will drop by ≥50 % and TEER measured in Ussing chambers will rise from ~8 Ω·cm² (aged baseline) to ≥15 Ω·cm², matching young adult values.
- Co‑administration of a PXR antagonist (ketoconazole) or AhR antagonist (CH‑223191) will abolish the IPA‑induced OCR improvement and barrier rescue, confirming pathway dependence.
Falsifiable outcome If intermediate‑dose IPA fails to improve mitochondrial respiration or barrier metrics in aged mice, or if the benefits are lost only when PXR or AhR is blocked, the hypothesis is refuted. Conversely, a rescue accompanied by exacerbated mitochondrial dysfunction at higher doses would reinforce the biphasic dosing model and highlight the therapeutic window.
Why this advances the field Current literature treats IPA‑PXR as anti‑inflammatory and AhR as mucosal‑immunity focused, yet ignores their convergent impact on mitochondrial health in senescence. By linking receptor activation to mitophagy and NRF2 signaling, we provide a mechanistic bridge that explains how a microbial metabolite can simultaneously quell inflammaging, preserve epithelial integrity, and avoid the energetic toxicity observed with chronic high‑dose exposure. This hypothesis can be addressed with existing tools—aged mouse models, Seahorse analysis, senescence staining, and Ussing‑chamber TEER—making it immediately testable for a Karolinska‑trained experimentalist.
References (implicitly cited):
- ACS JAFC 2020 IPA tight junction study [https://pubs.acs.org/doi/abs/10.1021/acs.jafc.0c05205]
- PMC12375546 PXR knockout colitis [https://pmc.ncbi.nlm.nih.gov/articles/PMC12375546/]
- PMC5959752 PXR inhibition of TLR4/NF‑κB [https://pmc.ncbi.nlm.nih.gov/articles/PMC5959752/]
- PMC12375546 AhR‑PXR synergy for mucus [https://pmc.ncbi.nlm.nih.gov/articles/PMC12375546/]
- PMC12375546 UC patient IPA/AhR correlation [https://pmc.ncbi.nlm.nih.gov/articles/PMC12375546/]
- Front Med 2021 mitochondrial respiration impairment [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.648259/full]
- Sci Adv 2023 IPA‑producing bacteria and cognition [https://www.science.org/doi/10.1126/sciadv.adw8410]